An infographic titled "Exalgo® Hydromorphone HCI Extended-Release Tablets (CII)". It is divided into three sections.<br /><br />The first section is titled "How many concomitant medications is your chronic pain patient taking? Exalgo has reduced potential for certain drug-drug interactions". The second section has an illustration of the liver and the text "Unlike oxycodone EXALGO is not metabolized through the CYP450 pathway". The third section has a list of key takeaways and a link to the website "exalgo.com".<br /><br />At the bottom of the infographic there is a section titled "Key Takeaways" which provides information about the benefits of using Exalgo® HCI extended-release tablets. The infographic also mentions that the tablets are available for purchase at a discounted price.

Description

An infographic titled "Exalgo® Hydromorphone HCI Extended-Release Tablets (CII)". It is divided into three sections.

The first section is titled "How many concomitant medications is your chronic pain patient taking? Exalgo has reduced potential for certain drug-drug interactions". The second section has an illustration of the liver and the text "Unlike oxycodone EXALGO is not metabolized through the CYP450 pathway". The third section has a list of key takeaways and a link to the website "exalgo.com".

At the bottom of the infographic there is a section titled "Key Takeaways" which provides information about the benefits of using Exalgo® HCI extended-release tablets. The infographic also mentions that the tablets are available for purchase at a discounted price.

Type